Substance Use Disorder Treatment in the Time of COVID by Shanahan, Christopher W & Halpin, Susan M.
University of Massachusetts Medical School 
eScholarship@UMMS 
Network of the National Library of Medicine 
New England Region (NNLM NER) Repository 
Network of the National Library of Medicine 
New England Region 
2021-01-28 
Substance Use Disorder Treatment in the Time of COVID 
Christopher W. Shanahan MD, MPH, FACP 
Boston University School of Medicine 
Et al. 
Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/ner 
 Part of the Library and Information Science Commons, Public Health Commons, and the Substance 
Abuse and Addiction Commons 
Repository Citation 
Shanahan CW, Halpin SM. (2021). Substance Use Disorder Treatment in the Time of COVID. Network of 
the National Library of Medicine New England Region (NNLM NER) Repository. https://doi.org/10.13028/
zba8-f315. Retrieved from https://escholarship.umassmed.edu/ner/89 
Creative Commons License 
This work is licensed under a Creative Commons Attribution 4.0 License. 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Network of the 
National Library of Medicine New England Region (NNLM NER) Repository by an authorized administrator of 
eScholarship@UMMS. For more information, please contact Lisa.Palmer@umassmed.edu. 
1
Substance Use Disorder Treatment 
in the Time of COVID
To view the captions click on 
the URL in the chat box.
This webinar is being recorded. 
About this Webinar
▪ All participants have been muted when 
entering the webinar
▪ Closed captioning is available, click on 
the captioning link in the chat box.
▪ This webinar is being recorded. You will 
receive an email with a link to the 
webinar recording and presentation 
materials in about a week.
▪ You will have an opportunity to ask 
questions during the last 15 minutes. Jot 
down your questions as the webinar is in 
progress and use the Chat Box for 




▪ Medical Librarians and some Nurses 
are eligible for 1 CE credit for 
attending this webinar. Nurses check 
This Link to make sure your state 
accepts the CEs for attending this 
webinar
▪ Completing an evaluation at the end 
of the webinar is required for you to 
receive CE credit. The evaluation 
should open automatically as you 
leave the webinar. 
▪ Use the Enrollment Code provided at 
the end of the webinar to claim your 
CE credit.
Hello!
Your Webinar Host - Susan Halpin, M.Ed.
Education & Outreach Coordinator
Network of the National Library of Medicine 
New England Region, 




National Library of Medicine (NLM)
https://www.nlm.nih.gov/
Physical library is Bethesda, MD part of the 
NIH campus. 
Largest biomedical library in the world.
One of the federal government’s largest 
providers of digital content.
The library is open to everyone.
NLM’s Mission
To advance the progress of medicine and improve 
public health by providing everyone equal access to 
biomedical & health information resources and data.
NNLM Outreach 
NLM Carries Out its Mission 
Through the Network of the National Libraries of Medicine (NNLM)
https://nnlm.gov/
Nationwide network of health sciences libraries, 
public libraries & information centers 
Each region has a partnership with a regional 
medical library
Outreach provided through:
• Free access to online resources
• Free Training 
• Grant funding
77,000 people received training from NNLM last year!
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▪ Support evidence-based practices & medication Rx’ing to treat 
Chronic Pain or SUD (CP/SUD)
▪Consult on the following:
▪ Prescribing buprenorphine, naltrexone or long-acting opioid
▪ Medication changes or therapeutic titration
▪ Overall management plan for complex, challenging cases
▪ Review Tx changes before, during, and/or after patient visits 
▪ Miscellaneous issues: Pregnant women & Special populations
▪ Free, personalized, real-time coaching
▪ Initial & FU consultation & longitudinal coaching prn.
▪ Info on community resources to address patient needs
▪Build capacity to care patients with CP/SUD
MCSTAP: What it is, How we can help, When to callMCSTAP Mission: To support 
primary care teams in increasing 
th ir ca acity for, & c mfort in, 
using evidence-based practices in 
screening for, diagnosing, treating, 
& managing the care of all atients 
with chronic pain &/or SUD 
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Ten (10) Physician Consultants (PCs) from 
different health systems across Massachusetts
Highly qualified with:
• Expertise treating CP/SUD
• Experience teaching & mentoring providers
• Deep commitment to helping others work for 
better outcomes for patients with CP/SUD
The MCSTAP team
Learning Objectives
Audience members who attend this will be able to:
▪ Understand the bidirectional relationship of SARS-Cov-2 pandemic 
& the epidemic U.S. Substance Use on identification & treatment 
of physical, mental health, & Substance Use Disorders (SUD) (e.g. 
opioid crisis)
▪ Describe components & impact of Social Determinants of Health 
(SDOH) on care of individuals with SUD & impact on the risk for & 
clinical outcomes of SARS-CoV-2 infection
▪ Employ Intersectionality to identify/analyze key areas of need & 
potential for high impact & then develop/implement evidence-
based & innovative solutions
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Outline
▪ Impact of Substance Use Disorder
▪ Frontline Adaptation & Innovation
▪Conceptual Tools to Analyze Impact of Co-Epidemic 
on SUD Treatment




The Broad Impact of Substance Use Disorder
Clinical Impact




▪ Mental illness (Anxiety, Depression, PTSD, etc.)
Social Impact
▪ Disrupted relationships in multiple domains: 
▪ Interpersonal [family, friends, etc.]
▪ Work problems




▪ Underemployment / Unemployment / Unemployability
16
Schulte MT, Hser YI. Substance Use and Associated Health Conditions 
throughout the Lifespan. Public Health Rev. 2014;35(2)
Regier DA, et.al.. JAMA. 1990 Nov 21;264(19):2511-8. PMID: 2232018.
Frontline Adaptation & Innovation        SUD X SARS-CoV-2
Patient-Centered Approach (Harm Reduction Perspective)
▪ More flexible approach to MOUD prescribing & diversion
▪ Urine Drug Testing: New Guidance
▪ Telehealth visits
▪ Remote (non-face-to-face) prescribing for new patients 
▪ OTP Take-home policies (Methadone)
▪ Increased awareness of need to address SDOH as part of 
associated SUD treatment activities
Practice Innovations
▪ Telehealth / Virtual Visiting (More administrative flexibility)
▪ More selective & targeted monitoring 
▪ E.g. urine drug testing, # days filled, # of Refills, etc.
▪ Remote testing services considered if indicated
17
Regulation Changes for Telehealth SUD X SARS-CoV-2
Ryan Haight Online Pharmacy Consumer Protection Act of 2008:
▪ Rules for telemedicine Rx of controlled medications. 
Drug Enforcement Agency (DEA): 
▪ Public health emergency enabled DEA to permit all DEA-registered clinicians to prescribe 
schedule II - V controlled substances (e.g. buprenorphine) to treat  OUD in patients prior to 
first in-person clinic visit.
US Dept. Health and Human Services (DHHS):
▪ Waived HIPAA penalties for “good faith use of telehealth.”
42 CFR, part 2:
▪ Behavioral Health not applicable in medical emergencies as deemed by the clinician
▪ SAMSHA:
▪ OTPs may Rx buprenorphine via telehealth & liberalized the # of days of take-home meds to 
reduce in-person visits.
▪ CMS:
▪ Temporarily allowing Medicare to cover additional telehealth services.
18
Lin L, et.al.  JAMA Psychiatry. 2020;77(12):1209–1210. 
Guidance Documents SUD X SARS-CoV-2
American Society of Addiction Medicine (ASAM) COVID-19 Task Force:
•Recommendations - Caring For Patients During The Covid-19 Pandemic: 
Adjusting Drug Testing Protocols
Centers for Disease Control (CDC): 
•Guideline for Prescribing Opioids for Chronic Pain — United States, 2016
•Quality Improvement and Care Coordination: Implementing the CDC 
Guideline for Prescribing Opioids for Chronic Pain
California Health Care Foundation: 
•Guidelines for Medication for Addiction Treatment for Opioid Use Disorder 




Lin L, et.al.  JAMA Psychiatry. 2020;77(12):1209–1210. 
Other Resource Pages  SUD X SARS-CoV-2
Brandeis Opioid Resource Connector: Communities informing communities
https://opioid-resource-connector.org/frontpage/
Primary Care: On the Front Lines of the Opioid Epidemic 
https://ldi.upenn.edu/sites/default/files/pdf/Primary Care - On the Front Line of the Opioid 
Epidemic. Issue Brief August 2016_0.pdf
Medication-Assisted Treatment Models of Care for Opioid Use Disorder in 
Primary Care Settings
https://www.ncbi.nlm.nih.gov/books/NBK402352/
Managing Pain Safely: Tapering Toolkit for Providers 
http://www.partnershiphp.org/Providers/HealthServices/Documents/ManagingPainSafely/T
APERINGTOOLKIT_FINAL.pdf
CMS opioid prescribing tool - Medicare
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Lin L, et.al.  JAMA Psychiatry. 2020;77(12):1209–1210. 
Wang, Q.Q., Kaelber, D.C., Xu, R. et al.  
Mol Psychiatry 26, 30–39 (2021)
21 Substance Use Disorders & COVID-19 Susceptibility
Analysis of 73 million patients (SUD: 10.3%; COVID-19: 12,030) 
▪ Persons with SUDs at  risk of contracting/suffering worse consequences 
from COVID-19 (esp. African Americans) 
▪ Of those with COVID-19, 15.6% had SUD vs. 10.3% did not. 
▪ Risk of COVID-19 highest in persons w/ new SUD Dx in the past year
▪ In persons w/ recent SUDs Dx vs Not more likely to have COVID-19: 
OUD: 10.2 X; Tobacco UD 8.2 X; Alcohol UD 7.8 X; Cocaine UD 6.5 X; Cannabis UD 5.3 X
▪ Persons w/ lifetime SUD 1.5 X more likely to have COVID-19 
▪ Persons w/ SUDs more likely to have COVID-19 vs. those w/o: 
OUD: 2.4 X; CUS 1.6 X; AUD 1.4 X; TUD (smoking or vaping) 1.3 X 
▪ Patients w/ lifetime SUD Dx’s more severe clinical outcomes from COVID-19
e.g. hospitalization (41% vs 30%) & death (9.6% vs 6.6%). 
▪ Of persons w/ lifetime SUD & COVID-19, the death rate of African Americans 
was 13 % vs 8.6 % for Caucasians 
z
Understanding the complexity 
& Intersectionality of 
Substance Use Disorder Care 
During a Pandemic: 
Key Concepts
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Social Determinants of Health
Social determinants of health (SDOH) have a major impact on 
people’s health, well-being, & quality of life. Examples include:
▪ Safe housing, transportation, and neighborhoods
▪ Access to nutritious foods & physical activity opportunities
▪ Racism, discrimination, & violence
▪ Education, job opportunities, and income
▪ Polluted air & water
▪ Language & literacy skills
Healthy People 2030
23











▪ Evolving Drug Policy
▪ Decarceration
▪ Social/Physical distancing
▪ Other Cowan, E., Khan, M.R., Shastry, S. et al. Conceptualizing the effects of the COVID-19 pandemic on people 
with opioid use disorder: an application of the social ecological model. Addict Sci Clin Pract 16, 4 (2021)
Social Ecological Model of Factor Impacting the Health of 
Individuals with Opioid Use Disorder from COVID-19
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An analytical framework for understanding how    
aspects of a person's social & political 
identities combine to create different 
modes of discrimination & privilege1,2
The interconnected nature of social 
categorizations (race, class, & gender) as they       
apply to a given individual or group, regarded as 
creating overlapping & interdependent systems of 
discrimination or disadvantage3
Domains: gender, sex, race, class, sexuality, religion, 
disability, physical appearance, & height
25 Intersectionality
1. Abigail A, "How Much is Being Attractive Worth?". Smithsonian Magazine. Retrieved 6/22/2020.
2. Yonce K "Attractiveness privilege : the unearned advantages of physical attractiveness". (Jan 2014)
3. Oxford English Dictionary (2015)
Personal Healthcare Systems (SUD Treatment)
Screening: Evidence-based tools (e.g. TAPS, COMM, ORT, etc.) 
Diagnosis: DSM-5 (11 Criteria)
Assessment: ASSIST, AUDIT, DAST, ASAM Levels of Care, etc.
Harm Reduction (Patient-Centered Care)
Treatment:
▪ “Detox” > Stabilization > Treatment (Inpatient, Outpatient) 
▪ Medication for Use Disorders (e.g. MOUD)
▪ Cognitive Behavioral Therapy (CBT)





• HALT (Hungry, Angry, Lonely, & Tired) 
• Mindfulness Meditation
• Know Your Triggers
• Join a Support Group
• Grounding Techniques
• Deep Breathing
• Make An Emergency Contact List




▪ Assess, Surveil, & Track Population Health





▪ Create, champion, & implement Policies / 
Plans / Laws
▪ Use legal & regulatory action
Assurance
▪ Enable equitable Access
▪ Develop a diverse & skilled workforce
▪ Improve & Innovate (Evaluation, Research, QI)
▪ Build/maintain organizational public health 
infrastructure  
• Framework protects & promotes health of all people in all communities. 
• To achieve equity, actively promote policies, systems, & community 
conditions that enable optimal health for all & seek to remove systemic 
& structural barriers resulting in health inequities. 
• Barriers: poverty, racism, gender discrimination, ableism, etc. 
• All people should have a fair & just opportunity to achieve optimal 
health & well-being.
The Public Health National Center for Innovations (PHNCI) 2020
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Impact of SAR-CoV-2 on SUD Population









Individual A E I
Network B f J
Community C g K
Structural D h L
Cowan E, et.al., Addict Sci Clin Pract. 2021, PMCID: PMC7789072.
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Domains of Impact
▪ Key / Relevant Issues
▪ Current Solutions / Approaches




SOCIAL DETERMINATES OF HEALTH
(SDOH )
COVID-SUD Intersectionality INDIVIDUAL X SDOH
Key / Relevant Issues 1,2
Biological or behavioral characteristics a/w individual’s risk of infection & 
associated morbidity & mortality (physical & mental health)
▪ Biological: Substance use related co-morbidity (e.g. lung disease) & immunosuppression. OUD > 
higher risk of SARS-CoV-2 diagnosis, hospitalization, & death
▪ Behavioral: Persons with SUD/OUD have exposure risk to SARS-CoV-2 d/t living conditions (e.g. 
Shelters, Unstable Housing, Shared Living spaces), Serious Mental Health conditions (e.g., 
bipolar,  anxiety, & antisocial personality disorder)2 as well as treatment environments (e.g. OTP), 
active use environments (Dealer, use sites, O.D. naloxone rescues) 
Current Solutions / Approaches
▪ Quarantine, Social Distancing, Temporary shelter, Masks, Vaccination, etc.
▪ Point-of-Use Drug testing
Knowledge / Communication Needs
▪ Comparison data on efficacy of current & potential transmission mitigation strategies
▪ Enhanced systems to assess & address both biological & behavioral risk

























Individual A F K
Network B G L
Community C H M
Structural D I N
1. Cowan E, et.al., Addict Sci Clin Pract. 2021, PMCID: 7789072
2. Schulte MT, Hser YI., Public Health Rev. 2014;35(2)
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COVID-SUD Intersectionality NETWORK X SDOH
Key / Relevant Issues: Networks can be both protective and risk factors
▪ Social Networks: (+) vs (-) family, friends, employment, other users (in & out of recovery / 
dealers, clinicians, etc. 
▪ Weakened relationships: Lead to  social contact leading to  SARS-CoV-2 exposure, MOUD, 
SUD, Mental health, & Harm reduction services ( depression, anxiety, psychosis, etc.)
▪ Drug Networks: Substance supply ’s >> to ’s in substance type, potency, contaminants, 
experience, etc.
▪ Network disruptions: Trigger adaptation/cessation of network-based interactions >> 
new/changed risk & benefits (e.g. type, frequency, form of administration, drug use setting; 
 contact with family decreases access to /use of substances. 
Current Solutions / Approaches
▪ Telehealth Services / Remote monitoring of Physical & Health care services, 
Virtual Self-help groups (AA)
▪ Increased case management
▪ Point-of-Use (PoU) Drug testing
Knowledge / Communication Needs
▪ Evidence-based/best practices: Telehealth / Remote monitoring / 
POU testing
▪ Network level illicit drug supply & O.D. monitoring and reporting
31
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Structural D I N
COVID-SUD Intersectionality           COMMUNITY X SDOH
Key / Relevant Issues
▪ Relationships of networks within defined boundaries (Service specific needs of at-risk 
populations e.g. housing/homelessness, treatment services, justice-involved/incarcerated) 
▪ Significant barriers to community d/t SDOH (no access/capacity for virtual service d/t lack of 
technology or internet. 
▪ Pandemic related economic collapse – high rates of job loss in at-risk populations 
Current Solutions / Approaches
▪ Telehealth / Privacy
▪ PPE for Safe street outreach
▪ Community / Coalition Programs
▪ Local Law enforcement, Fire fighters, & EMS
Knowledge / Communication Needs
▪ Telehealth/Remote monitoring evidence-based/best practices
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COVID-SUD Intersectionality STRUCTURAL X SDOH
Key / Relevant Issues
▪ Core community response: Laws, policies, societal values, & economics distributed non-
equitably (due to racial, class, etc. bias.) Implemented correctly can improve/exacerbate 
equitable delivery of services & opportunities
▪ Drug / Healthcare Policy: Changes to MOUD & Billing regulations (e.g. X-waiver, urine drug 
testing, face-to-face visits requirements/ Billing requirements) > increased flexibility 
▪ Decarceration: Prison release of high-risk person   risk of OD & Death within 30 days
▪ 2 yrs. post-release: Mortality rate: 777 deaths/100K person-yrs. 
▪ Adjusted Risk of Death (RoD) of former inmates 3.5 X > other state residents [95% CI] (3.2-
3.8). 
▪ RoD was 12.7 X [95% CI] (9.2-17.4) other state residents within 2 wks. post-release
▪  Relative RoD from drug O.D. (129 X, [95% CI, 89-186]) 
▪ Top causes of death: Drug O.D., Cardiovascular disease, Homicide, & Suicide.
Current Solutions / Approaches
▪ ’s to MOUD regulation >  access/flexibility vs  risk of O.D. or diversion
▪ Delivery of MOUD in prisons, Drug Courts, Bridge clinics, etc.
Knowledge / Communication Needs
▪ Evidence-based/best practices
33
Hawks L, Et.al.  JAMA Intern Med. 2020 Aug 1;180(8):1041-1042. 
PMID: 32343355.
Binswanger, IA, et.al., January 11, 2007, NEJM 2007; 356:157-165
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Structural D I N
COVID-SUD Intersectionality  INDIVIDUAL X PERSONAL HEALTH SYSTEMS
Key / Relevant Issues
▪ Effective & accessible healthcare focused on at-risk populations (SUD) reinforces 
messaging, monitoring, & management of individuals at high risk for SUD & SARS-
CoV-2 transmission to mitigate SARS-CoV-2 transmission
▪  degree & numbers of persons engaged in MOUD compared to before the 
pandemic has led to  rates of new HIV infection among OUD patients lost to 
follow-up b/o access constraints related to the pandemic
Current Solutions / Approaches
▪ Telehealth encounters
▪ Treatment of SUD (MOUD, Counseling, etc.)
Knowledge / Communication Needs
▪ Telehealth Evidence-based / Best practices
▪ Mechanism to  SUD treatment of At-risk individuals
35
36
Taylor JL, et.al. J of Substance Abuse Treatment, Vol 124,2021
IMPACT OF SARS-COV-2 ON HIV TRANSMISSION IN PATIENTS WITH SUD
37 IMPACT OF SARS-COV-2 ON HIV TRANSMISSION IN PATIENTS WITH SUD
Taylor JL, et.al. J of Substance Abuse Treatment, Vol 124,2021
COVID-SUD Intersectionality NETWORK X PERSONAL HEALTH SYSTEMS
Key / Relevant Issues
▪ Lack of connections to care networks b/o knowledge, socio-behavioral or 
insurance can both increase or decrease risks to medical & SUD treatment 
services
▪ Lack of access to care for personal health impacts knowledge, behaviors & 
access to treatment for persons with SUD 
Current Solutions / Approaches
▪ Outreach / Healthcare messaging
Knowledge / Communication Needs
▪ Evidence-based / Best Practices for leveraging all networks to provide 
timely & accurate knowledge sharing & messaging to increase access & 
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COVID-SUD Intersectionality        COMMUNITY X PERSONAL HEALTH SYSTEMS
Key / Relevant Issues
▪ Community resources can provide safe, evidence-based/best practices for 
treatment & harm reduction services, housing, employment, & medical care to at-
risk populations (decarerated, homeless, women, etc.)
▪ Disrupted community resources are a major risk to creating/maintaining critical 
medical, mental, public health surveillance systems & harm reduction services.
Current Solutions / Approaches
▪ Telemedicine / Street outreach / Testing
▪ PPE sourcing & distribution
Knowledge / Communication Needs
▪ Evidence-based / Best Practices for to leverage community resources to provide 
timely & accurate knowledge sharing & messaging to increase 
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COVID-SUD Intersectionality   STRUCTURAL X PERSONAL HEALTH SYSTEMS
Key / Relevant Issues
▪ Racial & socioeconomic bias is a basic mechanism that ensure that 
Structural Barriers to health care, SUD treatment & Social support impact 
at-risk SUD populations disproportionally. 
▪ Absence or presence of these barriers in the setting of the Pandemic has 
a major overall impact on clinical outcomes for treatment of SUD & SARS-
CoV-2 infection
Current Solutions / Approaches
▪ Laws and regulation designed to reduce/eliminate healthcare & health 
disparities 
Knowledge / Communication Needs
▪ Evidence-based / Best Practices for to address, mitigate/eliminate 
leverage community resources to provide timely & accurate 
knowledge sharing & impediments services & resources 
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COVID-SUD Intersectionality INDIVIDUAL X PUBLIC HEALTH SYSTEMS
Key / Relevant Issues
▪ Public health messaging is the mechanism that many/most individuals 
in community will obtain accurate and up-to-date information about 
the personal health of individuals in terms of SUD treatment & SARS-
CoV-2 prevention & treatment
Current Solutions / Approaches
▪ Medical & Behavioral messaging focused on prevention & accessing 
testing & treatment
Knowledge / Communication Needs
▪ Evidence-based / Best Practices to address, mitigate/eliminate 
leverage public health resources to provide
▪ Timely & accurate knowledge sharing 
▪ How to eliminate obstacles to implementing & accessing 
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COVID-SUD Intersectionality  NETWORK X PUBLIC HEALTH SYSTEMS
Key / Relevant Issues
▪ Networks can enhance/worsen Clinical, SUD, & SARS-CoV-2 related 
outcomes depending public health systems capacity to influence 
exacerbating/ameliorating factors. 
▪ Network-level approaches can address sub-group/population level risk; 
Potential for cost-effective outreach
Current Solutions / Approaches
▪ Public health messaging and knowledge transfer
Knowledge / Communication Needs
▪ Evidence-based / best practices to address, mitigate/eliminate leverage 
public health resources to provide
▪ How to eliminate obstacles to implementing & accessing 
services/resources that are mediated by structural inequity
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COVID-SUD Intersectionality COMMUNITY X PUBLIC HEALTH SYSTEMS
Key / Relevant Issues
▪ Community level interventions employing Public Health perspectives & 
community-targeted methods can help ensure engagement, knowledge of & access 
to healthcare, mental health, SUD treatment & support services. 
▪ Community focused efforts, while labor & time intensive approaches, they can 
ultimately produce successful/sustainable outcomes
▪ While the pandemic & substance use crises drive motivation to use these 
approaches but can also inhibit the execution/implementation
Current Solutions / Approaches
▪ Community engage community organizing and planning 
▪ Public health messaging & knowledge transfer
▪ Community / coalition programs
▪ Local Law enforcement, Fire fighters, & EMS
Knowledge / Communication Needs
▪ Evidence-based / best public health practices to leverage to provide 
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COVID-SUD Intersectionality STRUCTURAL X PUBLIC HEALTH SYSTEMS
Key / Relevant Issues
▪ Structural obstacles from racial & socioeconomic inequities impact access/delivery 
of health care, SUD treatment & Social support for at-risk SUD population. 
▪ Absence or presence of these barriers during the pandemic has a substantial 
impact on clinical outcomes for treatment of both SUD & SARS-CoV-2 infection
Current Solutions / Approaches
▪ Population-wide monitoring of clinical & public health outcomes a/w structural bias 
▪ Laws and regulation designed to reduce/eliminate healthcare & health disparities 
Knowledge / Communication Needs
▪ Evidence-based / best practices to address, mitigate, eliminate structural barriers
▪ Optimize leveraging of public health resources mitigate/eliminate structural 
obstacles 
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COVID-SUD Intersectionality PANDEMIC RELATED FACTORS
Stage of Pandemic determines risk in each model strata:
▪  Risk of SARS-CoV-2 infection >  risk of morbidity & mortality 
▪  Infection control >  social isolation/ risk of solo drug use /  SUD treatment/ MOUD
▪ Ongoing network disruptions can worsen other key intersectional domains
Current Solutions / Approaches
▪ Use of virtual/traditional personal & public health communications systems to transfer 
knowledge & enhance access to medical, mental health, & SUD services
▪ Transmission of knowledge & data to public-health focused community organizations
▪ Standard Medical research methods 
Knowledge / Communication Needs
▪ Improved, evidence-based / best Practices for communication to ensure timely / 
accurate knowledge sharing, mitigation of barriers to services & resources 
▪ Evidence-based / best practices to leverage community & network resources
▪ Pragmatic study design / implementation, guideline development
▪ Enhanced pandemic & population monitoring
46
Cowan E, et.al., Addict Sci Clin Pract. 2021, PMCID: 7789072
Summary
▪ The coincident SARS-CoV-2 pandemic & the substance use epidemic is 
complicated, bidirectional, & intersectional
▪ A patient-centered approach has been employed to guide both frontline 
as well as regulatory innovation
▪ The Social Ecological Model (SEM), applied as an organizing framework, 
can help characterize the interactions & impact on populations affected 
by the co-epidemics of SARS-CoV-2 & substance use
▪ Medical, psychiatric, substance use, & public health systems are 
activated & are rapidly evolving in response to the ongoing co-epidemic
▪ Challenges remain to address the needs of the science, medical, mental 
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